Clinical trials
Phase 3 Osteoporosis, Postmenopausal trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
73 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 6 |
| 2003 | 6 |
| 2004 | 7 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 5 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 67 |
| Unknown status | 4 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 14 |
| Eli Lilly and Company | 11 |
| Organon and Co | 7 |
| Hoffmann-La Roche | 4 |
| Radius Health, Inc. | 4 |
| GlaxoSmithKline | 3 |
| Novartis Pharmaceuticals | 3 |
| Warner Chilcott | 3 |
| Luye Pharma Group Ltd. | 2 |
| Merck Sharp & Dohme LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Osteoporosis, Postmenopausal | 73 |
| Osteoporosis | 24 |
| Bone Diseases, Metabolic | 11 |
| Fractures, Bone | 5 |
| Bone Diseases | 3 |
| Musculoskeletal Diseases | 3 |
| Back Pain | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Osteoporotic Fractures | 1 |
| Spinal Fractures | 1 |
Trials
Showing 76 to 73 of 73. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.